comscoreLonger Time to Chemotherapy Linked to Worse Outcomes in Triple-Negative Disease

Longer Time to Chemotherapy Linked to Worse Outcomes in Triple-Negative Disease

Zaidi Morante, MD explains her research on the timing of chemotherapy in women diagnosed with early-stage triple-negative breast cancer.
Dec 17, 2018
00:00
Download
00:00

Dr. Zaida Morante explains her research that found delaying chemotherapy for more than 30 days was associated with worse outcomes in women diagnosed with early-stage, triple-negative breast cancer. Triple-negative breast cancer is breast cancer that is estrogen-receptor-negative, progesterone-receptor-negative, and HER2-negative.

Listen to the podcast to hear Dr. Morante explain:

  • the design of the study

  • which outcomes delaying chemotherapy affected

  • possible explanations for why chemotherapy was delayed for some women

About the guest
 
morante zaida mug
Zaida Morante, MD

Dr. Zaida Morante is a medical oncologist at Instituto Nacional de Enfermedades Neoplásicas in Lima, Peru.

— Last updated on May 3, 2022, 3:03 PM

 
Lilly Oncology

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate